23:33 , Apr 19, 2019 |  BioCentury  |  Finance

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
21:41 , Apr 19, 2019 |  BC Extra  |  Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
21:38 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II

Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the product....
19:20 , Apr 19, 2019 |  BioCentury  |  Politics, Policy & Law

Thin U.S. biosimilars market fuels proposals to regulate biologics prices

Frustration over the failure of biosimilars to slash the costs of decades-old biologics has prompted a group of policy analysts to suggest abandoning attempts to copy biologics. Because the sole purpose of biosimilars is to...
18:42 , Apr 19, 2019 |  BC Week In Review  |  Company News

Concerto HealthAI, Pfizer to use real-world data, AI in precision cancer deal

Concerto HealthAI and Pfizer partnered to use artificial intelligence and real-world data to help identify patients who may benefit from new therapeutic combinations of the pharma's investigational and marketed therapies for solid tumors and hematologic...
17:22 , Apr 19, 2019 |  BC Week In Review  |  Company News

FDA approves Ibrance for men with breast cancer

Pfizer said FDA approved an sNDA for Ibrance palbociclib based on real-world data to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in men in combination with an aromatase inhibitor or fulvestrant. Pfizer Inc....
21:28 , Apr 18, 2019 |  BC Extra  |  Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

Arrakis raised $75 million in a series B round led by venBio and Nextech Invest. Also participating were new investors Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and Alexandria Venture...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
18:52 , Apr 17, 2019 |  BC Extra  |  Politics & Policy

Cummings defends drug price information request

House Energy & Commerce Committee Chairman Elijah Cummings (D-Md.) Wednesday denounced Jim Jordan (R-Ohio) for attempting to thwart the committee’s investigation into prescription drug prices. Cummings was responding to a letter Jordan sent on April...
23:17 , Apr 12, 2019 |  BC Extra  |  Clinical News

Clovis down after discontinuing rucaparib bladder cancer trial

Clovis was off $3.08 (13%) to $20.40 in after-hours trading Friday after the company disclosed that it discontinued the Phase II ATLAS trial of Rubraca rucaparib as monotherapy to treat locally advanced unresectable or metastatic...